123
Participants
Start Date
September 1, 2020
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
Tislelizumab
200 mg administered via intravenous (IV) infusion once every 3 weeks
Salvage Chemotherapy
Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
Beijing Cancer Hospital, Beijing
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Zhejiang Cancer Hospital, Hangzhou
Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou
Hunan Cancer Hospital, Changsha
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
BeiGene
INDUSTRY